Abstract
The effect of SARS-CoV-2 infection on response to mRNA-based SARS-CoV-2 vaccines is not well-described. We assessed longitudinal SARS-CoV-2-specific antibody responses pre- and post-vaccination among individuals with and without prior infection. The antibody response to the first vaccine dose was almost two-fold higher in individuals who were seropositive before vaccination compared to those who were seronegative, suggesting that prior infection primes the immune response to the first dose of mRNA-based vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://preprints.jmir.org/preprint/25410
Funding Statement
This study was supported by funds from the following sources: 1. 2007 Gillings Gift at the UNC Gillings School of Global Public Health (AEA) 2. North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill with funding from the North Carolina Coronavirus Relief Fund established and appropriated by the North Carolina General Assembly (EJC, RMB, RA, DRZ) 3. UNC School of Medicine (RMB) 4. A generous donation to the UNC School of Medicine by an anonymous donor (RMB) 5. National Institute of Occupational Safety and Health through Grant Award Number [75D30121P10086 0000HCCK-2021] (AEA, EJC) 6. National Science Foundation through Grant Award Number NSF 20-4353 (AEA) 7. National Institutes of Health through Grant Award Number R01 EB0225021 (AEA) 8. National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001111 supported the use of the REDCap database. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. In addition, EJC is supported by the National Heart, Lung, and Blood Institute through Grant Award Number [5T32HL007106-43], RMB is supported by the National Institute of Allergy and Infectious Diseases through Grant Award Number [5K23AI141764-03], and BES is supported by the University of North Carolina at Chapel Hill Center for AIDS Research (CFAR), an NIH funded program P30 AI050410. The funding organizations/sponsors were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of North Carolina Institutional Review Board #20-0942
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
1. New data points became available and were added. Figure 1 and the corresponding manuscript text were updated accordingly. The additional data did not change the findings of the study. 2. A supplementary figure was added that shows SARS-CoV-2-specific antibody responses by days from first (Panel a) and second (Panel b) vaccination. 3. Evans K. Lodge was added as an author. 4. Additional citations were added. 5. A statement was added regarding ethics review and informed consent. 6. The last paragraph was updated to clarify our interpretation of the study results. 7. We reformatted for journal specifications and made general editorial changes to the manuscript.
Data Availability
The study described in this manuscript is ongoing, and therefore, the data are not yet available to others. Once study follow-up is completed, the data will be made available by request.
